跳转至内容
Merck
CN
所有图片(1)

Key Documents

View All Documentation

SML2487

Sigma-Aldrich

Cabazitaxel

≥95% (HPLC)

别名:

1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-[[(tert-butoxy)carbonyl]amino]-2-hydroxy-3-phenylpropanoate], DEP cabazitaxel, Jevtana, TXD 258, XRP 6258, XRP-6258, dimethoxydocetaxel

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C45H57NO14
CAS号:
183133-96-2
分子量:
835.93
MDL编号:
MFCD18827611
UNSPSC代码:
12352200
NACRES:
NA.77

检测方案

≥95% (HPLC)

形式

powder

旋光性

[α]/D -36 to -44°, c = 0.5 in methanol

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

InChI

1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1

InChI key

BMQGVNUXMIRLCK-OAGWZNDDSA-N

生化/生理作用

Cabazitaxel is a synthetic taxane microtubule inhibitor and anticancer agent. It acts by stabilization of microtubules, promoting tubulin assembly into microtubules but inhibiting disassembly, resulting in the inhibition of mitotic and interphase cellular functions.

象形图

Health hazardExclamation mark
GHS08,GHS07

警示用语：

Warning

危险分类

Acute Tox. 4 Oral - Muta. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 2

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Patricia Vrignaud et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19(11), 2973-2983 (2013-04-17)
Taxanes are important chemotherapeutic agents with proven efficacy in human cancers, but their use is limited by resistance development. We report here the preclinical characteristics of cabazitaxel (XRP6258), a semisynthetic taxane developed to overcome taxane resistance. Cabazitaxel effects on purified
Maria J Martinez et al.
iScience, 26(9), 107681-107681 (2023-09-14)
Men with incurable castration resistant prostate cancer (CRPC) are typically treated with taxanes; however, drug resistance rapidly develops. We previously identified a clinically relevant seven gene network in aggressive CRPC, which includes the spindle assembly checkpoint (SAC) kinase BUB1. Since
Sheel A Patel et al.
OncoTargets and therapy, 10, 4089-4098 (2017-09-02)
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for
Takeo Kosaka et al.
Cancer chemotherapy and pharmacology, 82(6), 1061-1066 (2018-10-05)
The correlation of the oncological outcomes of docetaxel and cabazitaxel in Japanese metastatic castration-resistant prostate cancer (mCRPC) patients has not been unclear. This study included a total of 47 consecutive Japanese mCRPC patients treated with cabazitaxel and assessed the prognostic
Buse Cevatemre et al.
Cell death & disease, 15(2), 132-132 (2024-02-13)
The development of taxane resistance remains a major challenge for castration resistant prostate cancer (CR-PCa), despite the effectiveness of taxanes in prolonging patient survival. To uncover novel targets, we performed an epigenetic drug screen on taxane (docetaxel and cabazitaxel) resistant

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门